Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 13  •  04:00PM ET
0.2970
Dollar change
-0.0170
Percentage change
-5.41
%
Index
-
P/E
-
EPS (ttm)
-7.55
Insider Own
54.76%
Shs Outstand
24.19M
Perf Week
-5.20%
Market Cap
10.77M
Forward P/E
-
EPS next Y
-
Insider Trans
0.00%
Shs Float
16.41M
Perf Month
-12.34%
Enterprise Value
13.03M
PEG
-
EPS next Q
-
Inst Own
1.92%
Perf Quarter
-63.33%
Income
-125.52M
P/S
-
EPS this Y
-
Inst Trans
-0.96%
Perf Half Y
-66.63%
Sales
0.00M
P/B
-
EPS next Y
-
ROA
-212.74%
Perf YTD
-66.32%
Book/sh
-0.56
P/C
21.99
EPS next 5Y
-
ROE
-366.44%
52W High
5.50 -94.60%
Perf Year
-91.14%
Cash/sh
0.01
P/FCF
-
EPS past 3/5Y
20.66% -34.35%
ROIC
-
52W Low
0.15 96.30%
Perf 3Y
-97.44%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
9.21% 13.83%
Perf 5Y
-99.20%
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
25.24%
Oper. Margin
-
ATR (14)
0.05
Perf 10Y
-98.81%
Dividend Ex-Date
-
Quick Ratio
0.03
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
42.03
Recom
-
Dividend Gr. 3/5Y
- -
Current Ratio
0.03
EPS Q/Q
82.91%
SMA20
-7.73%
Beta
0.33
Target Price
-
Payout
-
Debt/Eq
-
Sales Q/Q
-
SMA50
-12.47%
Rel Volume
0.03
Prev Close
0.31
Employees
29
LT Debt/Eq
-
Earnings
-
SMA200
-72.50%
Avg Volume
21.91M
Price
0.30
IPO
Feb 02, 2015
Option/Short
Yes / Yes
EPS/Sales Surpr.
- -
Trades
Volume
687,964
Change
-5.41%
May-04-26 10:30AM
09:35AM
Apr-24-26 10:30AM
Apr-15-26 10:30AM
09:10AM
10:30AM Loading…
Apr-07-26 10:30AM
09:05AM
Mar-26-26 08:50AM
Mar-19-26 09:57AM
Feb-19-26 08:30AM
Feb-17-26 03:22PM
Feb-13-26 08:31AM
Feb-09-26 11:14AM
09:15AM
Jan-27-26 10:36AM
09:30AM Loading…
Jan-26-26 09:30AM
Dec-18-25 09:00AM
Dec-09-25 07:45AM
Nov-25-25 07:45AM
Nov-14-25 04:44PM
Nov-05-25 09:22AM
Oct-30-25 09:32AM
Oct-16-25 09:45AM
09:15AM
Oct-06-25 09:15AM
Sep-25-25 08:30AM
Sep-24-25 04:50PM
Sep-11-25 07:00AM
Sep-09-25 08:47AM
Sep-08-25 08:50AM
10:05AM Loading…
Sep-04-25 10:05AM
Aug-27-25 09:45AM
Aug-08-25 10:45AM
Jul-29-25 03:01PM
Jul-28-25 10:38AM
Jul-17-25 09:15AM
Jul-09-25 08:00AM
Jun-30-25 09:21AM
Jun-10-25 11:13AM
Jun-03-25 09:15AM
May-23-25 09:17AM
May-22-25 09:41PM
03:12PM
11:05AM
May-14-25 09:15AM
May-13-25 09:15AM
Apr-22-25 09:20AM
Apr-09-25 09:25AM
Apr-05-25 12:10PM
Apr-04-25 09:40AM
Mar-03-25 09:15AM
09:00AM
Feb-26-25 01:25PM
09:15AM
Feb-19-25 10:10AM
Jan-07-25 09:15AM
09:15AM
Jan-06-25 09:15AM
09:10AM
Dec-30-24 09:00AM
Dec-23-24 09:00AM
Dec-20-24 03:40PM
09:00AM
Nov-04-24 08:31AM
Oct-17-24 09:15AM
Oct-16-24 09:28AM
Sep-19-24 09:00AM
Sep-17-24 09:00AM
Sep-13-24 09:00AM
Sep-11-24 09:15AM
Jul-26-24 07:36AM
05:30AM
Jun-14-24 09:06AM
May-24-24 09:20AM
08:45AM
May-16-24 08:53AM
Apr-30-24 11:00AM
Apr-24-24 09:00AM
Apr-18-24 08:45AM
Mar-04-24 09:00PM
Feb-15-24 09:25AM
Feb-14-24 10:01AM
Feb-13-24 09:46AM
09:31AM
Jan-25-24 12:45PM
Jan-18-24 09:30AM
Jan-16-24 08:00AM
Nov-28-23 08:30AM
Nov-23-23 09:30AM
Nov-22-23 10:44AM
Nov-21-23 08:30AM
Nov-14-23 09:00AM
Nov-10-23 08:30AM
Nov-07-23 08:30AM
Oct-24-23 09:00AM
Oct-11-23 09:25AM
08:30AM
Oct-10-23 08:00AM
Oct-04-23 09:00AM
Oct-02-23 12:05PM
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.